Immunotherapy for osteosarcoma: Where do we go from here?

Pediatr Blood Cancer. 2018 Sep;65(9):e27227. doi: 10.1002/pbc.27227. Epub 2018 Jun 19.

Abstract

Osteosarcoma is the most common bone tumor in children and young adults, with few advances in survival and treatment, especially for metastatic disease, in the last 30 years. Recently, immunotherapy has begun to show promise in various adult cancers, but the utility of this approach for osteosarcoma remains relatively unexplored. In this review, we outline the mechanisms and status of immunotherapies currently in clinical trials as well as future therapies on the horizon, and discuss their potential application for osteosarcoma.

Keywords: immunotherapy; osteosarcoma; sarcoma.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Antineoplastic Agents, Immunological / therapeutic use
  • B7-H1 Antigen / antagonists & inhibitors
  • Biomarkers, Tumor
  • Bone Neoplasms / therapy*
  • CTLA-4 Antigen / antagonists & inhibitors
  • Cancer Vaccines / therapeutic use
  • Child
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Dendritic Cells / transplantation
  • Forecasting
  • Humans
  • Immunotherapy / methods*
  • Immunotherapy, Adoptive
  • Molecular Targeted Therapy / methods
  • Oncolytic Virotherapy
  • Osteosarcoma / immunology
  • Osteosarcoma / therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Treatment Outcome
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Cancer Vaccines
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor